Cardiff Oncology, Inc. financial data

Symbol
CRDF on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
11055 Flintkote Avenue, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Trovagene, Inc. (to 5/7/2020), TrovaGene Inc. (to 3/4/2013), XENOMICS INC (to 6/3/2009), USED KAR PARTS INC (to 6/30/2004)
Latest financial report
Q1 2024 - May 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 802 % -43.1%
Debt-to-equity 15.8 % +67.6%
Return On Equity -54.5 % -52.9%
Return On Assets -47.1 % -44.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.7 M shares +0.11%
Common Stock, Shares, Outstanding 44.7 M shares +0.07%
Entity Public Float 64.3 M USD -31.4%
Common Stock, Value, Issued 4 K USD 0%
Weighted Average Number of Shares Outstanding, Basic 44.7 M shares +0%
Weighted Average Number of Shares Outstanding, Diluted 44.7 M shares +0%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 610 K USD +54.4%
Operating Income (Loss) -44.3 M USD -8.35%
Nonoperating Income (Expense) 4.06 M USD +109%
Net Income (Loss) Attributable to Parent -40.2 M USD -3.33%
Earnings Per Share, Basic -0.9 USD/shares -1.12%
Earnings Per Share, Diluted -0.9 USD/shares -1.12%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 18.7 M USD +24.2%
Cash, Cash Equivalents, and Short-term Investments 67.2 M USD -30.7%
Accounts Receivable, after Allowance for Credit Loss, Current 393 K USD -41.9%
Assets, Current 70 M USD -31.2%
Property, Plant and Equipment, Net 1.2 M USD -9.17%
Operating Lease, Right-of-Use Asset 1.57 M USD -25.6%
Other Assets, Noncurrent 1.28 M USD -6.32%
Assets 74 M USD -30.5%
Accounts Payable, Current 5.19 M USD +78.1%
Employee-related Liabilities, Current 1.23 M USD +25.5%
Accrued Liabilities, Current 5.96 M USD +30.8%
Liabilities, Current 11.8 M USD +45.3%
Operating Lease, Liability, Noncurrent 1.3 M USD -31.5%
Liabilities 13.1 M USD +30.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -132 K USD -73.7%
Retained Earnings (Accumulated Deficit) -349 M USD -12.7%
Stockholders' Equity Attributable to Parent 60.9 M USD -36.9%
Liabilities and Equity 74 M USD -30.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.74 M USD +10.6%
Net Cash Provided by (Used in) Financing Activities 107 K USD
Net Cash Provided by (Used in) Investing Activities 4.64 M USD -36.7%
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 44.7 M shares +0.07%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3 M USD -125%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 18.7 M USD +24.2%
Deferred Tax Assets, Valuation Allowance 39.2 M USD +30.2%
Deferred Tax Assets, Gross 39.5 M USD +29.3%
Operating Lease, Liability 2.15 M USD -20.8%
Payments to Acquire Property, Plant, and Equipment 80 K USD +900%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.3 M USD -5.29%
Lessee, Operating Lease, Liability, to be Paid 2.4 M USD -23.6%
Property, Plant and Equipment, Gross 5.05 M USD +5.75%
Operating Lease, Liability, Current 696 K USD +2.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 775 K USD +2.79%
Lessee, Operating Lease, Liability, to be Paid, Year One 691 K USD +2.22%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 249 K USD -41%
Lessee, Operating Lease, Liability, to be Paid, Year Three 796 K USD +2.71%
Deferred Tax Assets, Operating Loss Carryforwards 23.4 M USD +15.5%
Preferred Stock, Shares Authorized 20 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 136 K USD -82.9%
Operating Lease, Payments 730 K USD +1.96%
Additional Paid in Capital 410 M USD +0.96%
Depreciation, Depletion and Amortization 102 K USD +13.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 4.57 M USD +9.62%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%